Sign In
NASDAQ:HBIO
Harvard Bioscience Stock Earnings Reports
$1.31
-0.0300 (-2.24%)
At Close: Feb 12, 2025
Harvard Bioscience Earnings Calls
Q4 2024
(Upcoming)
| Release date | Mar 06, 2025 |
| EPS estimate | $0.0700 |
| EPS actual | - |
| Revenue estimate | 24.15M |
| Revenue actual | - |
| Expected change | +/- 10.51% |
Q3 2024
Missed
-$0.0200 (-140.00%)
| Release date | Nov 07, 2024 |
| EPS estimate | $0.0500 |
| EPS actual | -$0.0200 |
| EPS Surprise | -140.00% |
| Revenue estimate | 24.15M |
| Revenue actual | 21.97M |
| Revenue Surprise | -9.03% |
Q2 2024
Missed
-$0.0300 (-160.00%)
| Release date | Aug 08, 2024 |
| EPS estimate | $0.0500 |
| EPS actual | -$0.0300 |
| EPS Surprise | -160.00% |
| Revenue estimate | 26.4M |
| Revenue actual | 23.097M |
| Revenue Surprise | -12.51% |
Q1 2024
Missed
$0.0200 (-14.27%)
| Release date | May 07, 2024 |
| EPS estimate | $0.0233 |
| EPS actual | $0.0200 |
| EPS Surprise | -14.27% |
| Revenue estimate | 25.79M |
| Revenue actual | 24.512M |
| Revenue Surprise | -4.96% |
Last 4 Quarters for Harvard Bioscience
Below you can see how HBIO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Missed
| Release date | May 07, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $3.75 |
| EPS estimate | $0.0233 |
| EPS actual | $0.0200 |
| EPS surprise | -14.27% |
| Date | Price |
|---|---|
| May 01, 2024 | $3.82 |
| May 02, 2024 | $3.82 |
| May 03, 2024 | $3.85 |
| May 06, 2024 | $3.92 |
| May 07, 2024 | $3.75 |
| May 08, 2024 | $3.68 |
| May 09, 2024 | $3.56 |
| May 10, 2024 | $3.53 |
| May 13, 2024 | $3.39 |
| 4 days before | -1.83% |
| 4 days after | -9.60% |
| On release day | -1.87% |
| Change in period | -11.26% |
Q2 2024
Missed
| Release date | Aug 08, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $3.12 |
| EPS estimate | $0.0500 |
| EPS actual | -$0.0300 |
| EPS surprise | -160.00% |
| Date | Price |
|---|---|
| Aug 02, 2024 | $2.98 |
| Aug 05, 2024 | $2.84 |
| Aug 06, 2024 | $2.91 |
| Aug 07, 2024 | $2.79 |
| Aug 08, 2024 | $3.12 |
| Aug 09, 2024 | $2.91 |
| Aug 12, 2024 | $2.95 |
| Aug 13, 2024 | $2.89 |
| Aug 14, 2024 | $2.81 |
| 4 days before | 4.70% |
| 4 days after | -9.94% |
| On release day | -6.73% |
| Change in period | -5.70% |
Q3 2024
Missed
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $2.39 |
| EPS estimate | $0.0500 |
| EPS actual | -$0.0200 |
| EPS surprise | -140.00% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $2.40 |
| Nov 04, 2024 | $2.37 |
| Nov 05, 2024 | $2.39 |
| Nov 06, 2024 | $2.82 |
| Nov 07, 2024 | $2.39 |
| Nov 08, 2024 | $2.57 |
| Nov 11, 2024 | $2.45 |
| Nov 12, 2024 | $2.28 |
| Nov 13, 2024 | $2.17 |
| 4 days before | -0.417% |
| 4 days after | -9.21% |
| On release day | 7.53% |
| Change in period | -9.58% |
Q4 2024
(Upcoming)
| Release date | Mar 06, 2025 |
| Fiscal end date | Dec 30, 2024 |
| Price on release | - |
| EPS estimate | $0.0700 |
| EPS actual | - |
| Date | Price |
|---|---|
| Feb 06, 2025 | $1.48 |
| Feb 07, 2025 | $1.45 |
| Feb 10, 2025 | $1.41 |
| Feb 11, 2025 | $1.34 |
| Feb 12, 2025 | $1.31 |
Harvard Bioscience Earnings Call Transcript Summary of Q3 2024
Q3 2024 Earnings Call
Financial Performance
- Revenue: Q3 revenue of $22 million, down 13% year-over-year and 5% sequentially, primarily influenced by weakness in China and the Asia Pacific region.
- Gross Margin: Achieved 58.1%, close to the target of 60%, despite low revenue.
- Operating Loss: Reported a GAAP operating loss of $1.9 million; adjusted operating income was $800,000 (3.8% of revenue).
- Adjusted EBITDA: Totaled $1.3 million (6% of revenue), down from $2.2 million year-over-year, mainly due to lower gross margin dollars.
- Cash Flow: Reported cash used in operations of $0.8 million, a decline compared to $4.4 million cash provided during Q3 of the previous year.
Market Dynamics
- Regional Insights:
- Americas: Revenue was down 12% year-over-year but showing signs of stabilization.
- Europe: Similar 12% decline year-over-year but stable sequentially.
- Asia Pacific: Revenue down 20%, with significant challenges remaining, particularly among CROs and pharma sectors.
- Expectations indicate moderate improvement in demand in Q4.
Operational Updates
- Successfully transitioned to a modern ERP system across U.S. operations, expected to enhance supply chain management and reduce operational delays.
- Additional $1 million in quarterly operating expense reductions expected to take effect starting Q4.
Product Development and New Segments
- Introduced new products including:
- SoHo Telemetry Devices: Expected to drive demand in government labs and CROs.
- VivaMARS Neurobehavioral Monitoring System: Successful delivery to Labcorp, with potential for expanded use.
- BTX Electroporation System: Growth noted in bioproduction applications, particularly from a major pharma customer.
- Mesh MEA Platforms: Positioned for significant growth in organoid research, with expected high adoption rates and recurring revenue potential.
Guidance and Future Outlook
- Revenue Guidance Reduced: 2024 revenue estimated to be between $93 million to $96 million, with Q4 expected between $23 million to $26 million.
- Anticipated Q4 gross margins of 59% to 60% and mid-teens in adjusted EBITDA margins.
- Optimism for sustained growth beyond 2024, particularly with new product introductions expected to drive revenue.
Key Takeaways for Investors
- The company is adjusting to recent market challenges but shows signs of stabilization, particularly in Europe and the Americas.
- Focus on new product introductions could lead to significant growth opportunities in the biopharma sector, providing potential upside in revenue.
- Operational efficiencies and ongoing cost management strategies suggest improved profitability moving forward.
Harvard Bioscience Earnings History
Earnings Calendar
FAQ
When is the earnings report for HBIO?
Harvard Bioscience (HBIO) has scheduled its earnings report for Mar 06, 2025 before the markets open.
What is the HBIO price-to-earnings (P/E) ratio?
HBIO P/E ratio as of Feb 12, 2025 (TTM) is -4.32.
What is the HBIO EPS forecast?
The forecasted EPS (Earnings Per Share) for Harvard Bioscience (HBIO) for the first fiscal quarter 2024 is $0.0700.
What are Harvard Bioscience's retained earnings?
On its balance sheet, Harvard Bioscience reported retained earnings of $21.97 million for the latest quarter ending Sep 30, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
